Amarin Reports Third Quarter 2022 Financial Results and Provides Business Update
-- U.S. Business Trends Stabilize and Progress on Operational Initiatives Result in Extended Cash Runway -- -- Commenced Launch of VAZKEPA® (icosapent ethyl) in England & Wales Mid-October As Planned – -- Obtained Positive Scientific Assessment for Reimbursement in Italy and the Netherlands &